Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cord Blood Microtransplantation + AZA in Advanced MDS/CMML/sAML
NCT05584761Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of unrelated umbilical cord blood in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Overall Survival Rate at 2 years, Complete Response Rate and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
unrelated umbilical cord blood
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05584761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584761.